Introduction {#sec1}
============

Imidazopyridine, an important class of nitrogen-containing fused heterocyclic motif, is widely present in plant alkaloids and natural products.^[@ref1]^ It is used in pharmaceutical chemistry as well as in materials science.^[@ref2]^ Thus, the development of versatile methods for the synthesis and functionalization of imidazopyridines is an important field of research in medicinal and synthetic organic chemistry.^[@ref3],[@ref4]^ Over the past decades, considerable efforts have been devoted for the incorporation of nitrogen functionality in heterocyclic motifs because of their wide applications in industry and pharmacology.^[@ref5]^ Conventionally, aromatic C--N bond formation relies on the transition-metal-catalyzed C--N cross-coupling reactions, such as Ullmann--Goldberg, Buchwald--Hartwig, and Chan--Lam amination.^[@ref6]^ These reactions require high temperature and prefunctionalization of starting materials. Transition-metal-catalyzed or visible light-induced direct C--H aminations are another efficient atom-economical coupling processes.^[@ref7],[@ref8]^ Direct amination is the direct incorporation of amine or amine derivatives to a carbon atom through the formation of C--N bond. Beside these, one more promising strategy of direct C--N couplings of heteroarenes with preactivated amino precursors has also been reported.^[@ref9]^

Over the past decade, the use of *N*-fluorobenzenesulfonimide (NFSI) for the amination of aromatic C(sp^2^)--H bond,^[@ref10],[@ref11]^ alkenes or unsaturated ketones,^[@ref12]^ and benzylic or allylic C--H bond^[@ref13]^ has been intensely studied by using Pd and Cu catalysts. NFSI can act as a source of both fluoronium cation for fluorination and nucleophilic nitrogen or nitrogen radical for amination.^[@ref14]^ So far, few groups have explored the transition-metal-catalyzed amination of arenes with NFSI ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}a).^[@ref10]^ Recently, Pan and co-workers described a copper-catalyzed imidation of heterocycles such as thiophene, furan, and pyrrole with NFSI ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}b).^[@ref11]^ Despite these successes, the imidation of other biologically relevant heterocycles using NFSI under metal-free mild conditions still remains an interesting and challenging subject for researchers.

![Direct Amination of Aromatic C--H Bond Using NFSI](ao-2018-020884_0002){#sch1}

Hypervalent iodines(III) are useful oxidants in various coupling reactions.^[@ref15]^ Moreover, iodine(III)-mediated intramolecular and intermolecular oxidative aminations have also been explored to construct diverse heterocyclic compounds.^[@ref16],[@ref17]^ In this regard, solely di(pivaloyloxy)iodobenzene \[PhI(OPiv)~2~\]-mediated oxidative C--H imidation by Wang et al. is a mentionable work.^[@ref18]^ Here, the imidation of 8-acylaminoquinolines and anilides by NFSI has been carried out in tetrahydrofuran (THF) at 80 °C for 8 h under metal-free condition. Very recently, our group reported an efficient method for a regioselective (diacetoxy)iodobenzene (PIDA)-mediated oxidative amination of imidazopyridines through C(sp^2^)--H functionalization leading to 3-amino-substituted imidazopyridines.^[@cit4c]^ As a part of our ongoing investigations on functionalization of imidazoheterocycles,^[@ref4]^ herein, we described a metal-free PIDA-mediated regioselective imidation of imidazoheterocycles with NFSI ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}c).

Results and Discussion {#sec2}
======================

2-Phenylimidazo\[1,2-*a*\]pyridine (**1a**) was initially selected as a model substrate with NFSI as an imidating reagent ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). At first, the reaction was carried out by taking **1a** (0.2 mmol) with NFSI (1.0 equiv) at 60 °C in 1,2-DCE for 15 min. However, no reaction took place, and both **1a** and NFSI were recovered ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). To our delight, in the presence of 1 equiv of PIDA, the reaction afforded *N*-(2-phenylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2a**) in 68% yield after 15 min ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 2). Further, the yield was not affected when the reaction was carried out for 1 h. Other solvents, such as THF, CH~3~CN, toluene, 1,4-dioxane, ethanol, chlorobenzene, and dimethylformamide (DMF), were also screened under the same conditions ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 3--9). Better result was obtained in toluene affording 89% of the desired product ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 5), whereas very low yield of the desired product was formed with bis(trifluoroacetoxy)iodobenzene (PIFA) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 10). Next, we checked the effect of different oxidants such as K~2~S~2~O~8~, TBHP, and H~2~O~2~ instead of PIDA ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 11--13). In all cases, only trace amount of imidated products were detected. The yield of the reaction was decreased with diminished loading of PIDA to 0.5 equiv but remained unchanged by increasing the amount to 1.5 equiv ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 14 and 15). No significant improvement of the yield was found with increasing the reaction temperature, but the yield was dropped when the reaction was carried out at 40 °C ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 16 and 17). A trace amount of the desired product **2a** were obtained at room temperature ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 18). Direct imidation product of toulene was not detected. Summing up, our study led to the following optimized conditions: 1 equiv of PIDA in toluene at 60 °C for 15 min ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 5).

###### Optimization for the Amination Reaction[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-020884_0008){#GRAPHIC-d7e346-autogenerated}

  entry                                oxidant (equiv)    solvent         yield[b](#t1fn2){ref-type="table-fn"} (%)
  ------------------------------------ ------------------ --------------- -------------------------------------------
  1                                                       1,2-DCE         0
  2                                    PIDA (1)           1,2-DCE         68
  3                                    PIDA (1)           THF             61
  4                                    PIDA (1)           CH~3~CN         66
  **5**                                **PIDA (1)**       **toluene**     **89**
  6                                    PIDA (1)           1,4-dioxane     78
  7                                    PIDA (1)           EtOH            33
  8                                    PIDA (1)           chlorobenzene   72
  9                                    PIDA (1)           DMF             67
  10                                   PIFA (1)           toluene         18
  11                                   K~2~S~2~O~8~ (1)   toluene         trace
  12                                   TBHP (1)           toluene         trace
  13                                   H~2~O~2~ (1)       toluene         trace
  14                                   PIDA (0.5)         toluene         41
  15                                   PIDA (1.5)         toluene         90
  16[c](#t1fn3){ref-type="table-fn"}   PIDA (1)           toluene         88
  17[d](#t1fn4){ref-type="table-fn"}   PIDA (1)           toluene         59
  18[e](#t1fn5){ref-type="table-fn"}   PIDA (1)           toluene         trace

Reaction conditions: **1a** (0.2 mmol), NFSI (1.0 equiv), and oxidant (1.0 equiv) in the presence of solvent (1 mL) at 60 °C for 15 min.

Isolated yields.

Reaction was carried out at 80 °C.

Reaction was carried out at 40 °C.

Reaction was carried out at rt.

With the optimized reaction conditions, we explored the substrate scope of the present protocol, as shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. A series of C-3 imidated imidazo\[1,2-*a*\]-pyridine products were obtained in good to excellent yields (**2a--2t**). Imidazo\[1,2-*a*\]-pyridines containing electron-donating substituents such as −CH~3~ and −OCH~3~ at different positions of the pyridine ring produced the desired products in excellent yields (**2b--2d**). Substrates possessing halogen substituents attached to the six-membered ring successfully underwent the reaction (**2e--2f**). 2-Phenyl-6-(trifluoromethyl)imidazo\[1,2-*a*\]pyridine successfully reacted with NFSI to furnish the desired product (**2g**). Next, we investigated the effect of substituents at the phenyl ring at the C-2 position of imidazo\[1,2-*a*\]pyridine. The phenyl moiety containing both electron-donating substituents and electron-withdrawing groups gave the corresponding products in high yields (**2h--2p**). Hydroxy-containing imidazo\[1,2-*a*\]pyridine was also tolerable for such transformation (**2q**). Both naphthyl- and heteroaryl-substituted imidazopyridines produced the desired products without any difficulties (**2r** and **2s**). The single-crystal X-ray diffraction study of *N*-(phenylsulfonyl)-*N*-(2-(thiophen-2-yl)imidazo\[1,2-*a*\]pyridin-3-yl)benzenesulfonamide (**2s**) was performed to confirm the structure of imidated imidazopyridine.^[@ref19]^ Isopropyl-substituted (C-2) imidazo\[1,2-*a*\]pyridine could also be successfully converted to the corresponding product in excellent yield (**2t**). Moreover, no desired imidated product was obtained when 3-phenylimidazo\[1,2-*a*\]pyridine (**1u**) was reacted with NFSI under the optimized reaction conditions. This result suggests that the reaction selectively took place at the C-3 position of imidazo\[1,2-*a*\]pyridine. We also performed the reactions of **1b**, **1e**, and **1f** with dibenzenesulfonimide \[HN(SO~2~Ph)~2~\] instead of NFSI under the same optimized conditions ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). Here, the corresponding products (**2b**, **2e**, and **2f**) were obtained in moderate yields. The gram-scale reaction was also carried out under the normal laboratory setup by taking 2-phenylimidazo\[1,2-*a*\]pyridine (**1a**) and NFSI under the standard reaction conditions on a 10 mmol scale. Gratifyingly, *N*-(2-phenylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2a**) was obtained without significant decrease in yield which clearly signifies the practicability of our present protocol.

![Substrate Scope of Imidazopyridines^a,b,c^\
Reaction conditions: 1 (0.2 mmol), NFSI (1.0 equiv), and PIDA (1.0 equiv) in toluene (1 mL) at 60 °C for 15 min.\
10 mmol scale.\
Reaction with HN(SO~2~Ph)~2~ instead of NFSI.](ao-2018-020884_0003){#sch2}

To extend the generality of this methodology, we investigated the present imidation reaction with other heterocycles such as imidazo\[2,1-*b*\]thiazole and benzo\[*d*\]imidazo\[2,1-*b*\]thiazoles ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}). Both 6-phenylimidazo\[2,1-*b*\]thiazole (**3a**) and 2-phenylbenzo\[*d*\]imidazo\[2,1-*b*\]thiazole (**3b**) reacted well to afford the desired products in satisfactory yields (**4a** and **4b**). 2-Phenylbenzo\[*d*\]imidazo\[2,1-*b*\]thiazole containing both electron-donating and electron-withdrawing substituents underwent the reaction with NFSI without any difficulties (**4c--4e**). Heteroaryl-substituted benzoimidazothiazole was also effective for such transformation to afford the desired imidated product in good yields (**4f**). However, 4,5-unsubstituted imidazoles (**3g** and **3h**) did not provide imidated products under the optimized reaction conditions. The reactions of imidazothiazole (**3a**) and benzoimidazothiazole (**3b**) with HN(SO~2~Ph)~2~ produced the desired imidated products (**4a** and **4b**) in lower yields ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

![Coupling of Imidazothiazole and Benzoimidazothiazole with NFSI^a,b^\
Reaction conditions: 3 (0.2 mmol), NFSI (1.0 equiv), and PIDA (1.0 equiv) in toluene (1 mL), at 60 °C for 15 min.\
Reaction with HN(SO~2~Ph)~2~ instead of NFSI.](ao-2018-020884_0004){#sch3}

The current methodology is also applicable for N-substituted indole and indolizine derivatives ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Both *N*-methylindole and 1-methyl-2-phenyl indole produced the desired products in high yields (**5a** and **5b**). Moreover, indolizine derivatives smoothly participated in this reaction to give the desired imidated products in good yields (**6a** and **6b**).

![Substrate scope with other heterocycles. Reaction conditions: N-substituted indoles or indolizines (0.2 mmol), NFSI (1.0 equiv), and PIDA (1.0 equiv) in toluene (1 mL) at 60 °C for 15 min.](ao-2018-020884_0001){#fig1}

Amino derivative of imidazopyridine (**7a**) could be easily synthesized from *N*-(2 phenylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2a**) using TfOH ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}).^[@cit14b]^

![Synthetic Utility](ao-2018-020884_0005){#sch4}

To acquire the mechanistic insights into the reaction pathway, few control experiments were carried out ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}). It was found that imidazo\[1,2-*a*\]pyridine failed to give the corresponding product in the presence radical scavengers such as 2,2,6,6-tetramethylpiperidine-1-oxyl, 2,6-di-*tert*-butyl-4-methylphenol, and *p*-benzoquinone ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}a). The use of a stoichiometric amount of 1,1-diphenylethylene was also completely suppressed the imidation reaction. Moreover, *N*-(2,2-diphenylvinyl)-*N*-(phenylsulfonyl)benzenesulfonamide (**8a**) was obtained in 53% yield along with almost full recovery of **1a** ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}b). These observations imply that the reaction proceeds through a radical pathway.

![Control Experiments](ao-2018-020884_0006){#sch5}

On the basis of the control experiments ([Scheme [5](#sch5){ref-type="scheme"}](#sch5){ref-type="scheme"}) as well as previous reports,^[@cit4c],[@ref18],[@ref20]^ a plausible mechanism of PIDA-mediated C--H imidation of imidazopyridines with NFSI is presented in [Scheme [6](#sch6){ref-type="scheme"}](#sch6){ref-type="scheme"}. Probably, the first step is the PIDA-mediated oxidation of imidazopyridine (**1a**) to imidazopyridine radical cation (**A**) along with the formation of radical (**B**) through a single electron-transfer process. After that the radical (**B**) is oxidized by NFSI via one-electron F-atom transfer pathway, affording the bis-sulfonylamidyl radical (**C**). On the other hand, dibenzenesulfonimide \[HN(SO~2~Ph)~2~\] could also produce *N*-iodoamido species (**D**) in the presence of PIDA which subsequently gives bis-sulfonylamidyl radical (**C**) and generates imidazopyridine radical cation (**A**) from **1a**. Finally, the resulting imidazopyridine radical cation (**A**) regioselectively coupled with the bis-sulfonylamidyl radical (**C**) to produce the imidazolenium ion (**E**) which consequently affords the product (**2a**) through the elimination of AcOH.

![Plausible Mechanistic Pathway](ao-2018-020884_0007){#sch6}

Conclusions {#sec3}
===========

In summary, we have developed an efficient and simple methodology for PIDA-mediated regioselective imidation of imidazo\[1,2-*a*\]pyridines using NFSI as the nitrogen source under metal-free conditions in short reaction times. The present methodology is also applicable to other heterocycles such as imidazo\[2,1-*b*\]thiazole, benzo\[*d*\]imidazo-\[2,1-*b*\]thiazole, indole, and indolizine derivatives. Metal-free conditions, broad substrates scope, fast reactions, and gram-scale synthesis are the notable advantages of our methodology. To the best of our knowledge, this is the first report of metal-free imidation of imidazoheterocycles using NFSI featuring the incorporation of −N(SO~2~Ph)~2~ group. We believe that our present protocol will open a new possibility for the forthcoming more practical and selective C--N bond formation route of heterocycles under metal-free conditions.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

All reagents were purchased from commercial sources and used without further purification. ^1^H NMR spectra were determined on a 400 MHz spectrometer as solutions in CDCl~3~. Chemical shifts are expressed in parts per million (δ), and the signals were reported as s (singlet), d (doublet), t (triplet), m (multiplet), dd (double of doublet), and coupling constants (*J*) were given in hertz. ^13^C{^1^H} NMR spectra were recorded at 100 MHz in CDCl~3~ solution. Chemical shifts as an internal standard are referenced to CDCl~3~ (δ = 7.26 for ^1^H and δ = 77.16 for ^13^C{^1^H} NMR) as an internal standard. Thin-layer chromatography (TLC) was done on a silica gel-coated glass slide. All solvents were dried and distilled before use. Commercially available solvents were freshly distilled before the reaction. All reactions involving moisture sensitive reactants were executed using an oven-dried glassware. X-ray single crystal data were collected using Mo Kα (λ = 0.71073 Å) radiation with a CCD area detector. Melting points were determined on a glass disk with an electrical bath and are uncorrected. All of the imidazoheterocycles were prepared by our reported method.^[@cit4b],[@cit4d]^

General Experimental Procedures for the Synthesis of **2a--2t** and **4a--4f** {#sec4.2}
------------------------------------------------------------------------------

Imidazoheterocycles (0.2 mmol), NFSI (1.0 equiv, 63 mg), and PIDA (1.0 equiv, 65 mg) were taken in an oven-dried reaction vessel equipped with a magnetic stir bar. Then, toluene (1 mL) was added and stirred at 60 °C for 15 min. The progress of the reaction was monitored by TLC. After completion, the reaction mixture was diluted with 8 mL of water/ethyl acetate (1:1). Then, the reaction mixture was extracted with ethyl acetate, and the organic phase was dried over anhydrous Na~2~SO~4~. After evaporating the solvent under reduced pressure, the crude residue was obtained. Finally, it was purified by column chromatography on silica gel (60--120 mesh) using petroleum ether/ethylacetate as an eluent to afford the pure imidated products (**2a--2t** and **4a--4f**).

### *N*-(2-Phenylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2a**) {#sec4.2.1}

White solid (87 mg, 89%), *R*~*f*~ 0.5 (PET/EtOAc = 3:2), mp 128--130 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.92--7.90 (m, 4H), 7.72--7.70 (m, 2H), 7.64 (d, *J* = 8.8 Hz, 1H), 7.59--7.55 (m, 2H), 7.52--7.50 (m, 1H), 7.41--7.37 (m, 4H), 7.29--7.24 (m, 1H), 7.18--7.14 (m, 1H), 7.12--7.08 (m, 2H), 6.66--6.63 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 145.6, 144.6, 139.2, 134.7, 131.9, 129.2, 129.1, 128.5, 128.2, 127.6, 126.9, 124.0, 118.0, 112.8, 111.1; Anal. Calcd for C~25~H~19~N~3~O~4~S~2~: C, 61.34; H, 3.91; N, 8.58%. Found: C, 61.13; H, 4.02; N, 8.67%.

### *N*-(8-Methyl-2-phenylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2b**) {#sec4.2.2}

White solid (88 mg, 87%), *R*~*f*~ 0.6 (PET/EtOAc = 4:1), mp 116--118 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.92--7.90 (m, 4H), 7.75--7.73 (m, 2H), 7.56 (t, *J* = 7.6 Hz, 2H), 7.38 (t, *J* = 8.0 Hz, 5H), 7.17--7.08 (m, 3H), 7.05--7.03 (m, 1H), 6.55 (t, *J* = 6.8 Hz, 1H), 2.65 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 145.3, 144.8, 139.3, 134.6, 132.3, 129.2, 129.1, 128.3, 128.1, 128.0, 127.8, 125.5, 121.7, 112.7, 111.3, 16.6; Anal. Calcd for C~26~H~21~N~3~O~4~S~2~: C, 62.01; H, 4.20; N, 8.34%. Found: C, 62.21; H, 4.09; N, 8.25%.

### *N*-(7-Methyl-2-phenylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2c**) {#sec4.2.3}

White solid (87 mg, 86%), *R*~*f*~ 0.7 (PET/EtOAc = 4:1), mp 78--80 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.92--7.90 (m, 4H), 7.69--7.67 (m, 2H), 7.59--7.55 (m, 2H), 7.41--7.37 (m, 6H), 7.15--7.13 (m, 1H), 7.10--7.06 (m, 2H), 6.50--6.48 (m, 1H), 2.40 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 149.0, 145.0, 139.2, 134.7, 132.9, 132.0, 131.8, 129.2, 129.1, 128.4, 128.1, 127.6, 123.2, 116.5, 115.4, 21.4; Anal. Calcd for C~26~H~21~N~3~O~4~S~2~: C, 62.01; H, 4.20; N, 8.34%. Found: C, 62.27; H, 4.32; N, 8.13%.

### *N*-(7-Methoxy-2-phenylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2d**) {#sec4.2.4}

White solid (91 mg, 88%), *R*~*f*~ 0.5 (PET/EtOAc = 4:1), mp 96--98 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.92--7.90 (m, 4H), 7.68--7.66 (m, 2H), 7.58--7.55 (m, 2H), 7.41--7.37 (m, 4H), 7.28 (d, *J* = 7.6 Hz, 1H), 7.16--7.12 (m, 1H), 7.10--7.06 (m, 2H), 6.92 (d, *J* = 2.4 Hz, 1H), 6.35 (dd, *J* = 2.4, 7.2 Hz, 1H), 3.87 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 159.5, 146.3, 145.3, 139.2, 134.7, 131.9, 129.2, 129.1, 128.4, 128.1, 127.4, 124.4, 110.1, 107.7, 95.3, 55.8; Anal. Calcd for C~26~H~21~N~3~O~5~S~2~: C, 60.10; H, 4.07; N, 8.09%. Found: C, 59.95; H, 4.15; N, 7.99%.

### *N*-(6-Fluoro-2-phenylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2e**) {#sec4.2.5}

White solid (94 mg, 93%), *R*~*f*~ 0.5 (PET/EtOAc = 3:2), mp 130--132 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.93--7.91 (m, 4H), 7.71--7.69 (m, 2H), 7.62--7.58 (m, 3H), 7.43--7.39 (m, 4H), 7.36--7.35 (m, 1H), 7.19--7.16 (m, 2H), 7.12--7.09 (m, 2H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 153.4 (d, *J*~C--F~ = 238.0 Hz), 142.1, 139.1, 134.9, 134.1, 131.7, 129.2 (d, *J*~C--F~ = 19.0 Hz) 129.0, 128.7, 128.3, 127.5, 119.0, 118.8, 118.6 (d, *J*~C--F~ = 9.0 Hz), 111.4, 110.9; Anal. Calcd for C~25~H~18~FN~3~O~4~S~2~: C, 59.16; H, 3.57; N, 8.28%. Found: C, 59.30; H, 3.68; N, 8.12%.

### *N*-(6-Bromo-2-phenylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2f**) {#sec4.2.6}

White solid (104 mg, 92%), *R*~*f*~ 0.4 (PET/EtOAc = 3:2), mp 136--138 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.94--7.92 (m, 4H), 7.74--7.72 (m, 2H), 7.63--7.58 (m, 2H), 7.51 (d, *J* = 9.6 Hz, 1H), 7.44--7.40 (m, 5H), 7.32--7.29 (m, 1H), 7.18--7.16 (m, 1H), 7.13--7.09 (m, 2H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 142.6, 139.1, 135.1, 130.9, 129.3, 129.0, 128.8, 128.5, 128.4, 127.7, 127.0, 126.1, 124.2, 118.4, 108.1; Anal. Calcd for C~25~H~18~BrN~3~O~4~S~2~: C, 52.82; H, 3.19; N, 7.39%. Found: C, 52.61; H, 3.22; N, 7.48%.

### *N*-(2-Phenyl-6-(trifluoromethyl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2g**) {#sec4.2.7}

White solid (95 mg, 85%), *R*~*f*~ 0.6 (PET/EtOAc = 3:2), mp 124--126 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.93 (d, *J* = 7.6 Hz, 4H), 7.77--7.75 (m, 2H), 7.72 (d, *J* = 9.6 Hz, 1H), 7.65 (s, 1H), 7.62--7.59 (m, 2H), 7.43--7.37 (m, 5H), 7.22--7.19 (m, 1H), 7.13 (t, *J* = 7.6 Hz, 2H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 145.8 (d, *J*~C--F~ = 296.0 Hz), 139.0, 135.1, 131.2, 129.6, 129.4, 129.1, 129.0, 128.8, 128.7, 128.4, 127.7, 126.7, 122.9 (q, *J*~C--F~ = 6.0, 11.0 Hz), 122.7 (d, *J*~C--F~ = 2.0 Hz), 118.8; Anal. Calcd for C~26~H~18~F~3~N~3~O~4~S~2~: C, 56.01; H, 3.25; N, 7.54%. Found: C, 56.18; H, 3.21; N, 7.40%.

### *N*-(Phenylsulfonyl)-*N*-(2-(*p*-tolyl)imidazo\[1,2-*a*\]pyridin-3-yl)benzenesulfonamide (**2h**) {#sec4.2.8}

White solid (91 mg, 90%), *R*~*f*~ 0.5 (PET/EtOAc = 7:3), mp 120--122 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.92--7.90 (m, 4H), 7.64--7.56 (m, 5H), 7.49--7.47 (m, 1H), 7.41--7.37 (m, 4H), 7.27--7.23 (m, 1H), 6.90 (d, *J* = 8.0 Hz, 2H), 6.64--6.61 (m, 1H), 2.28 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 145.8, 144.5, 139.3, 138.8, 138.3, 134.5, 129.1, 129.0, 128.9, 127.5, 126.8, 123.9, 117.9, 112.6, 110.8, 21.2; Anal. Calcd for C~26~H~21~N~3~O~4~S~2~: C, 62.01; H, 4.20; N, 8.34%. Found: C, 61.78; H, 4.15; N, 8.46%.

### *N*-(8-Methyl-2-(*p*-tolyl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2i**) {#sec4.2.9}

White solid (97 mg, 94%), *R*~*f*~ 0.5 (PET/EtOAc = 4:1), mp 132--134 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.91 (dd, *J* = 0.6, 8.4 Hz, 4H), 7.26--7.55 (m, 4H), 7.40--7.33 (m, 5H), 7.03 (d, *J* = 6.8 Hz, 1H), 6.90 (d, *J* = 8.0 Hz, 2H), 6.53 (t, *J* = 6.8 Hz, 1H), 2.64 (s, 3H), 2.28 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 145.4, 144.8, 139.3, 138.0, 134.4, 129.3, 129.15, 129.11, 128.9, 127.9, 127.6, 125.5, 121.6, 112.6, 111.1, 21.3, 16.6; Anal. Calcd for C~27~H~23~N~3~O~4~S~2~: C, 62.65; H, 4.48; N, 8.12%. Found: C, 62.49; H, 4.41; N, 8.30%.

### *N*-(2-(4-Methoxyphenyl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2j**) {#sec4.2.10}

White solid (96 mg, 93%), *R*~*f*~ 0.3 (PET/EtOAc = 4:1), mp 119--121 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.94--7.92 (m, 4H), 7.67 (d, *J* = 8.8 Hz, 2H), 7.63--7.58 (m, 3H), 7.47--7.39 (m, 5H), 7.27--7.23 (m, 1H), 6.64--6.60 (m, 3H), 3.78 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 159.9, 145.5, 144.5, 139.3, 134.6, 129.29, 129.22, 129.1, 129.0, 126.8, 124.5, 123.8, 117.8, 113.7, 112.6, 55.3; Anal. Calcd for C~26~H~21~N~3~O~5~S~2~: C, 60.10; H, 4.07; N, 8.09. Found: C, 59.84; H, 4.15; N, 8.23%.

### *N*-(2-(4-Fluorophenyl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2k**) {#sec4.2.11}

White solid (95 mg, 94%), *R*~*f*~ 0.6 (PET/EtOAc = 7:3), mp 143--145 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.94--7.92 (m, 4H), 7.74--7.70 (m, 2H), 7.61 (t, *J* = 7.6 Hz, 3H), 7.48 (d, *J* = 6.8 Hz, 1H), 7.42 (t, *J* = 8.0 Hz, 4H), 7.30--7.26 (m, 1H), 6.79 (t, *J* = 8.8 Hz, 2H), 6.67--6.64 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 162.9 (d, *J*~C--F~ = 247.0 Hz), 144.7, 144.6, 139.2, 134.8, 129.5 (d, *J*~C--F~ = 8.0 Hz), 129.2, 129.1, 128.2 (d, *J*~C--F~ = 2.0 Hz), 127.0, 123.9, 118.0, 115.1 (d, *J*~C--F~ = 22.0 Hz), 112.8, 111.0; HRMS (ESI--TOF) *m*/*z*: \[M + H^+^\] calcd for C~25~H~18~FN~3~O~4~S~2~, 508.0795; found, 508.0798.

### *N*-(2-(4-Chlorophenyl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2l**) {#sec4.2.12}

White solid (96 mg, 92%), *R*~*f*~ 0.6 (PET/EtOAc = 7:3), mp 153--155 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.93--7.90 (m, 4H), 7.66--7.60 (m, 5H), 7.48--7.46 (m, 1H), 7.44--7.40 (m, 4H), 7.30--7.27 (m, 1H), 7.07--7.04 (m, 2H), 6.67--6.64 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 144.6, 144.5, 139.1, 134.8, 134.6, 130.4, 129.3, 129.1, 128.9, 128.4, 127.2, 126.5, 124.0, 118.1, 113.0; Anal. Calcd for C~25~H~18~ClN~3~O~4~S~2~: C, 57.30; H, 3.46; N, 8.02. Found: C, 57.43; H, 3.38; N, 8.11%.

### *N*-(2-(3-Bromophenyl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2m**) {#sec4.2.13}

White solid (108 mg, 95%), *R*~*f*~ 0.5 (PET/EtOAc = 7:3), mp 145--147 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.84--7.82 (m, 4H), 7.75--7.74 (m, 1H), 7.61--7.49 (m, 5H), 7.34 (t, *J* = 8.0 Hz, 4H), 7.24--7.18 (m, 2H), 6.89 (t, *J* = 8.0 Hz, 1H), 6.64--6.61 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 144.6, 144.0, 138.8, 134.8, 134.0, 132.2, 131.5, 130.4, 129.6, 129.2, 129.0, 127.2, 126.1, 124.1, 122.4, 118.1, 113.1; Anal. Calcd for C~25~H~18~BrN~3~O~4~S~2~: C, 52.82; H, 3.19; N, 7.39%. Found: C, 52.59; H, 3.07; N, 7.28%.

### *N*-(Phenylsulfonyl)-*N*-(2-(4-(trifluoromethyl)phenyl)imidazo\[1,2-*a*\]pyridin-3-yl)benzenesulfonamide (**2n**) {#sec4.2.14}

White solid (89 mg, 80%), *R*~*f*~ 0.6 (PET/EtOAc = 3:2), mp 131--133 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.92 (dd, *J* = 0.8, 8.0 Hz, 4H), 7.84 (d, *J* = 8.0 Hz, 2H), 7.67 (d, *J* = 9.2 Hz, 1H), 7.61--7.57 (m, 2H), 7.50 (d, *J* = 6.8 Hz, 1H), 7.42--7.34 (m, 7H), 6.71--6.68 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 145.8 (d, *J*~C--F~ = 218.0 Hz), 139.1, 135.0, 130.3, 130.0, 129.2 (d, *J*~C--F~ = 18.0 Hz), 128.7, 128.5, 127.8, 127.4, 126.6, 125.4, 125.1 (q, *J*~C--F~ = 5.0, 9.0 Hz), 124.0, 118.3, 113.2; Anal. Calcd for C~26~H~18~F~3~N~3~O~4~S~2~: C, 56.01; H, 3.25; N, 7.54%. Found: C, 56.20; H, 3.33; N, 7.45%.

### *N*-(2-(3-Nitrophenyl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2o**) {#sec4.2.15}

White solid (89 mg, 83%), *R*~*f*~ 0.6 (PET/EtOAc = 3:2), mp 155--157 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 8.47--7.46 (m, 1H), 8.06--8.04 (m, 1H), 7.94--7.91 (m, 1H), 7.86 (d, *J* = 7.6 Hz, 4H), 7.62--7.59 (m, 1H), 7.52--7.48 (m, 3H), 7.33 (t, *J* = 8.0 Hz, 4H), 7.29--7.19 (m, 2H), 6.68--6.65 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 148.2, 144.7, 142.8, 138.9, 134.9, 133.2, 132.2, 132.1, 129.3, 129.1, 128.6, 127.6, 124.1, 123.1, 122.4, 118.2, 113.4; Anal. Calcd for C~25~H~18~N~4~O~6~S~2~: C, 56.17; H, 3.39; N, 10.48%. Found: C, 56.03; H, 3.36; N, 10.53%.

### *N*-(2-(4-Cyanophenyl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2p**) {#sec4.2.16}

White solid (77 mg, 75%), *R*~*f*~ 0.7 (PET/EtOAc = 3:2); mp 156--158 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.96--7.94 (m, 4H), 7.88--7.86 (m, 2H), 7.68--7.64 (m, 3H), 7.51--7.44 (m, 5H), 7.41--7.39 (m, 2H), 7.36--7.31 (m, 1H), 6.73--6.69 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 144.8, 143.2, 139.0, 136.5, 135.0, 132.7, 131.9, 129.4, 129.1, 127.9, 127.5, 124.0, 118.8, 118.3, 113.3, 111.7; Anal. Calcd for C~26~H~18~N~4~O~4~S~2~: C, 60.69; H, 3.53; N, 10.89%. Found: C, 60.54; H, 3.44; N, 10.76%.

### *N*-(2-(2-Hydroxyphenyl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2q**) {#sec4.2.17}

White solid (74 mg, 73%), *R*~*f*~ 0.4 (PET/EtOAc = 7:3), mp 139--140 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 12.9 (br s, 1H), 7.96 (dd, *J* = 0.8, 8.4 Hz, 4H), 7.64--7.56 (m, 4H), 7.45 (t, *J* = 8.0 Hz, 4H), 7.35--7.31 (m, 1H), 7.23--7.21 (m, 1H), 7.07--7.02 (m, 1H), 6.90--6.88 (m, 1H), 6.73--6.69 (m, 1H), 6.28--6.24 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 158.1, 144.2, 142.2, 139.1, 135.2, 135.0, 130.6, 129.3, 129.2, 127.7, 126.7, 123.8, 118.4, 117.5, 117.0, 114.2, 113.4; Anal. Calcd for C~25~H~19~N~3~O~5~S~2~: C, 59.39; H, 3.79; N, 8.31%. Found: C, 59.16; H, 3.84; N, 8.17%.

### *N*-(2-(Naphthalen-2-yl)imidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2r**) {#sec4.2.18}

White solid (85 mg, 79%), *R*~*f*~ 0.5 (PET/EtOAc = 7:3), mp 150--152 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 8.14 (s, 1H), 7.84--7.78 (m, 5H), 7.65--7.53 (m, 3H), 7.50 (d, *J* = 8.0 Hz, 2H), 7.38--7.28 (m, 4H), 7.22--7.15 (m, 5H), 6.62--6.58 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 145.5, 144.7, 139.1, 134.5, 133.3, 133.0, 132.2, 129.1, 129.0, 128.8, 128.6, 127.7, 127.3, 127.09, 127.06, 126.5, 125.8, 125.2, 124.0, 118.0, 112.9; Anal. Calcd for C~29~H~21~N~3~O~4~S~2~: C, 64.55; H, 3.92; N, 7.79%. Found: C, 64.41; H, 3.85; N, 7.92%.

### *N*-(Phenylsulfonyl)-*N*-(2-(thiophen-2-yl)imidazo\[1,2-*a*\]pyridin-3-yl)benzenesulfonamide (**2s**) {#sec4.2.19}

White solid (85 mg, 86%), *R*~*f*~ 0.4 (PET/EtOAc = 7:3); mp 137--139 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.90--7.88 (m, 4H), 7.53 (t, *J* = 8.0 Hz, 3H), 7.38--7.34 (m, 5H), 7.20--7.16 (m, 1H), 7.09 (d, *J* = 5.2 Hz, 1H), 6.99--6.98 (m, 1H), 6.62--6.55 (m, 2H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 144.6, 141.2, 139.5, 134.8, 134.6, 129.2, 129.0, 128.9, 127.8, 127.1, 126.7, 126.1, 123.7, 117.8, 112.9; HRMS (ESI--TOF) *m*/*z*: \[M + H^+^\] calcd for C~23~H~17~N~3~O~4~S~3~, 496.0454; found, 496.0455.

### *N*-(2-Isobutylimidazo\[1,2-*a*\]pyridin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**2t**) {#sec4.2.20}

White solid (80 mg, 85%), *R*~*f*~ 0.5 (PET/EtOAc = 8:2), mp 83--85 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.97 (d, *J* = 7.2 Hz, 4H), 7.73--7.69 (m, 2H), 7.55 (t, *J* = 7.6 Hz, 6H), 7.24--7.20 (m, 1H), 6.67--6.63 (m, 1H), 2.23--2.20 (m, 1H), 1.89 (d, *J* = 7.2 Hz, 2H), 0.84 (d, *J* = 6.4 Hz, 6H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 149.3, 144.7, 139.1, 134.7, 129.4, 129.1, 128.9, 126.3, 123.4, 117.5, 112.5, 35.7, 27.2, 22.8; Anal. Calcd for C~23~H~23~N~3~O~4~S~2~: C, 58.83; H, 4.94; N, 8.95%. Found: C, 58.97; H, 5.02; N, 8.83%.

### *N*-(6-Phenylimidazo\[2,1-*b*\]thiazol-5-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**4a**) {#sec4.2.21}

White solid (74 mg, 75%), *R*~*f*~ 0.4 (PET/EtOAc = 4:1), mp 118--120 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.92--7.89 (m, 4H), 7.59--7.54 (m, 4H), 7.42--7.38 (m, 4H), 7.13--7.06 (m, 3H), 6.70--6.66 (m, 2H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 150.1, 147.2, 138.9, 134.7, 131.9, 129.9, 129.2, 128.9, 128.2, 128.1, 126.8, 118.1, 113.1; Anal. Calcd for C~23~H~17~N~3~O~4~S~3~: C, 55.74; H, 3.46; N, 8.48%. Found: C, 55.62; H, 3.50; N, 8.31%.

### *N*-(2-Phenylbenzo\[*d*\]imidazo\[2,1-*b*\]thiazol-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**4b**) {#sec4.2.22}

White solid (85 mg, 78%), *R*~*f*~ 0.5 (PET/EtOAc = 4:1), mp 144--146 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.97--7.95 (m, 4H), 7.67--7.65 (m, 2H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.56--7.52 (m, 2H), 7.35 (t, *J* = 8.4 Hz, 4H), 7.22--7.19 (m, 1H), 7.11--7.09 (m, 1H), 7.07--7.03 (m, 2H), 6.91--6.89 (m, 2H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 147.4, 138.9, 134.7, 131.8, 130.2, 129.9, 129.6, 129.0, 128.9, 128.5, 128.2, 128.1, 127.0, 125.7, 124.9, 123.8, 114.5; Anal. Calcd for C~27~H~19~N~3~O~4~S~3~: C, 59.43; H, 3.51; N, 7.70%. Found: C, 59.69; H, 3.64; N, 7.61%.

### *N*-(7-Methyl-2-phenylbenzo\[*d*\]imidazo\[2,1-*b*\]thiazol-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**4c**) {#sec4.2.23}

White solid (90 mg, 80%), *R*~*f*~ 0.6 (PET/EtOAc = 4:1); mp 135--137 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.95 (dd, *J* = 0.8, 8.4 Hz, 4H), 7.65--7.62 (m, 2H), 7.54 (t, *J* = 7.6 Hz, 2H), 7.41 (s, 1H), 7.35 (t, *J* = 8.0 Hz, 4H), 7.10--7.02 (m, 3H), 6.78 (d, *J* = 8.4 Hz, 1H), 6.70 (dd, *J* = 0.8, 8.8 Hz, 1H), 2.37 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 147.1, 138.9, 135.1, 134.7, 131.9, 130.0, 129.9, 129.6, 129.0, 128.5, 128.16, 128.11, 126.9, 126.7, 123.8, 114.1, 113.9, 21.3; Anal. Calcd for C~28~H~21~N~3~O~4~S~3~: C, 60.09; H, 3.78; N, 7.51%. Found: C, 59.80; H, 3.71; N, 7.65%.

### *N*-(7-Methoxy-2-phenylbenzo\[*d*\]imidazo\[2,1-*b*\]thiazol-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**4d**) {#sec4.2.24}

White solid (83 mg, 72%), *R*~*f*~ 0.4 (PET/EtOAc = 4:1), mp 170--172 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.95 (d, *J* = 7.2 Hz, 4H), 7.64--7.62 (m, 2H), 7.54 (t, *J* = 7.6 Hz, 2H), 7.35 (t, *J* = 8.0 Hz, 4H), 7.12--7.01 (m, 4H), 6.80 (d, *J* = 8.8 Hz, 1H), 6.46 (dd, *J* = 2.4, 9.2 Hz, 1H), 3.80 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 157.0, 138.9, 134.7, 132.0, 131.3, 129.5, 129.1, 128.8, 128.3, 128.1, 128.0, 126.8, 126.5, 126.1, 115.1, 113.1, 107.9, 55.9; Anal. Calcd for C~28~H~21~N~3~O~5~S~3~: C, 58.42; H, 3.68; N, 7.30%. Found: C, 58.64; H, 3.74; N, 7.22%.

### *N*-(7-Chloro-2-phenylbenzo\[*d*\]imidazo\[2,1-*b*\]thiazol-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**4e**) {#sec4.2.25}

White solid (81 mg, 70%), *R*~*f*~ 0.3 (PET/EtOAc = 4:1), mp 125--127 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.96--7.94 (m, 4H), 7.65--7.60 (m, 2H), 7.58--7.54 (m, 2H), 7.37 (t, *J* = 8.0 Hz, 4H), 7.31--7.28 (m, 1H), 7.12--7.10 (m, 1H), 7.08--7.03 (m, 2H), 6.89--6.86 (m, 1H), 6.82 (d, *J* = 8.8 Hz, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 138.8, 134.8, 131.6, 130.5, 129.6, 129.5, 129.49, 129.44, 129.1, 128.3, 128.2, 128.0, 127.5, 126.9, 126.0, 123.5, 115.1; Anal. Calcd for C~27~H~18~ClN~3~O~4~S~3~: C, 55.90; H, 3.13; N, 7.24%. Found: C, 56.14; H, 3.05; N, 7.08%.

### *N*-(Phenylsulfonyl)-*N*-(2-(thiophen-2-yl)benzo\[*d*\]imidazo\[2,1-*b*\]thiazol-3-yl)benzenesulfonamide (**4f**) {#sec4.2.26}

White solid (75 mg, 68%), *R*~*f*~ 0.7 (PET/EtOAc = 7:3); mp 132--134 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 8.01 (dd, *J* = 1.2, 8.8 Hz, 4H), 7.62--7.56 (m, 3H), 7.42--7.38 (m, 4H), 7.21 (t, *J* = 7.2 Hz, 1H), 7.11 (dd, *J* = 0.8, 4.8 Hz, 1H), 6.97--6.96 (m, 1H), 6.93--6.89 (m, 1H), 6.83 (d, *J* = 8.0 Hz, 1H), 6.64--6.62 (m, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 139.2, 134.7, 131.8, 129.9, 129.5, 129.1, 127.8, 127.5, 126.0, 125.8, 125.1, 125.0, 124.4, 123.8, 123.7, 114.3, 110.9; Anal. Calcd for C~25~H~17~N~3~O~4~S~4~: C, 54.43; H, 3.11; N, 7.62%. Found: C, 54.68; H, 3.02; N, 7.47%.

### *N*-(1-Methyl-1*H*-indol-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**5a**) {#sec4.2.27}

White solid (65 mg, 76%), *R*~*f*~ 0.4 (PET/EtOAc = 4:1); mp 78--80 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.94--7.91 (m, 4H), 7.72--7.68 (m, 2H), 7.59--7.53 (m, 5H), 7.31--7.27 (m, 2H), 7.17--7.13 (m, 1H), 6.23 (s, 1H), 3.33 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 138.8, 136.4, 134.4, 129.2, 128.9, 127.2, 125.7, 123.7, 121.7, 120.4, 110.2, 104.7, 29.2; Anal. Calcd for C~21~H~18~N~2~O~4~S~2~: C, 59.14; H, 4.25; N, 6.57. Found: C, 59.05; H, 4.19; N, 6.64%.

### *N*-(1-Methyl-2-phenyl-1*H*-indol-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**5b**) {#sec4.2.28}

White solid (79 mg, 79%), *R*~*f*~ 0.5 (PET/EtOAc = 4:1), mp 155--157 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.76--7.74 (m, 3H), 7.51 (t, *J* = 7.6 Hz, 3H), 7.37--7.25 (m, 10H), 7.22--7.16 (m, 1H), 6.93 (t, *J* = 7.6 Hz, 1H), 6.76 (d, *J* = 8.0 Hz, 1H), 3.54 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 142.2, 139.9, 135.9, 133.6, 130.5, 129.3, 129.1, 129.0, 128.9, 128.6, 128.4, 125.7, 122.7, 120.9, 119.3, 109.9, 31.4; HRMS (ESI--TOF) *m*/*z*: \[M + Na^+^\] calcd for C~27~H~22~N~2~O~4~S~2~, 525.0913; found, 525.0917.

### *N*-(1-Cyanoindolizin-3-yl)-*N*-(phenylsulfonyl)benzenesulfonamide (**6a**) {#sec4.2.29}

White solid (73 mg, 83%), *R*~*f*~ 0.6 (PET/EtOAc = 4:1), mp 120--122 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 7.87--7.85 (m, 4H), 7.76--7.70 (m, 3H), 7.68--7.65 (m, 1H), 7.58--7.54 (m, 4H), 7.21--7.17 (m,1H), 6.75--6.72 (m, 1H), 6.63 (s, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 138.3, 137.7, 134.9, 129.5, 128.7, 124.8, 123.5, 119.5, 118.0, 115.6, 114.0, 113.9, 82.2; Anal. Calcd for C~21~H~15~N~3~O~4~S~2~: C, 57.65; H, 3.46; N, 9.61. Found: C, 57.89; H, 3.41; N, 9.51%.

### Methyl-3-(*N*-(phenylsulfonyl)phenylsulfonamido)indolizine-1-carboxylate (**6b**) {#sec4.2.30}

White solid (73 mg, 78%), *R*~*f*~ 0.5 (PET/EtOAc = 4:1), mp 106--108 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 8.21 (dd, *J* = 0.8, 8.8 Hz, 1H), 7.86 (dd, *J* = 0.8, 8.0 Hz, 4H), 7.72--7.67 (m, 3H), 7.53 (t, *J* = 8.0 Hz, 4H), 7.16--7.12 (m, 1H), 6.91 (s, 1H), 6.68--6.64 (m, 1H), 3.87 (s, 3H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 164.7, 138.6, 135.8, 134.6, 129.3, 128.8, 124.6, 123.0, 119.8, 118.9, 113.4, 103.7, 51.2; Anal. Calcd for C~22~H~18~N~2~O~6~S~2~: C, 56.16; H, 3.86; N, 5.95%. Found: C, 56.39; H, 3.81; N, 6.04%.

### 2-Phenylimidazo\[1,2-*a*\]pyridin-3-amine (**7a**)^[@cit4f]^ {#sec4.2.31}

Gummy mass (35 mg, 84%), *R*~*f*~ 0.4 (PET/EtOAc = 3:2); ^1^H NMR (CDCl~3~, 400 MHz): δ 7.98--7.95 (m, 3H), 7.53 (d, *J* = 9.2 Hz, 1H), 7.47--7.43 (m, 2H), 7.33--7.29 (m, 1H), 7.11--7.07 (m, 1H), 6.79 (t, *J* = 6.8 Hz, 1H), 3.40 (br s, 2H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 143.9, 141.1, 134.6, 130.4, 129.1, 128.8, 127.2, 123.3, 121.9, 117.5, 111.8.

### *N*-(2,2-Diphenylvinyl)-*N*-(phenylsulfonyl)benzenesulfonamide (**8a**)^[@cit12a]^ {#sec4.2.32}

White solid (50 mg, 53%), *R*~*f*~ 0.3 (PET/EtOAc = 9:1); mp 122--124 °C; ^1^H NMR (CDCl~3~, 400 MHz): δ 8.00--7.98 (m, 3H), 7.69--7.67 (m, 3H), 7.59--7.55 (m, 5H), 7.38 (d, *J* = 8.0 Hz, 3H), 7.30 (s, 1H), 7.24--7.20 (m, 5H), 6.11 (s, 1H); ^13^C{^1^H} NMR (CDCl~3~, 100 MHz): δ 139.9, 138.7, 135.9, 133.9, 130.0, 129.5, 128.9, 128.7, 128.5, 116.4.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b02088](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b02088).Crystallographic data for compound **2s** ([CIF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b02088/suppl_file/ao8b02088_si_001.cif))Scanned copies of ^1^H and ^13^C{^1^H} NMR spectra of the synthesized compounds ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b02088/suppl_file/ao8b02088_si_002.pdf))
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